From the Orlando Health Cancer Institute, Orlando, FL (Laughlin, Havron, Shoup, Chu).
Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center - New Orleans, New Orleans, LA (Li, Yu, Wu, Yi, Hsieh).
School of Public Health, Louisiana State University Health Sciences Center - New Orleans, New Orleans, LA (Li, Yu, Wu, Yi, Hsieh).
Received December 12, 2022; Accepted December 13, 2022.
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Dr Laughlin’s spouse holds stock ownership in Moderna Therapeutics.
Support: Drs Yu and Hsieh are supported by the National Cancer Institute (award HHSN261201800007I/HHSN26100002). Dr Wu is supported by the National Institute of Health (award 2R15MD012387-02) and National Cancer Institute (award 3R01CA26098-02S1)
Presented at the Southern Surgical Association 134th Annual Meeting, Palm Beach, FL, December 2022.
Supplemental digital content is available for this article.
Correspondence address: Quyen D Chu, MD, MBA, FACS, 1400 S Orange Ave, Orlando, FL 32806. email [email protected]